Literature DB >> 15494432

Involvement of the urokinase-type plasminogen activator receptor in hematopoietic stem cell mobilization.

Carmine Selleri1, Nunzia Montuori, Patrizia Ricci, Valeria Visconte, Maria Vincenza Carriero, Nicolai Sidenius, Bianca Serio, Francesco Blasi, Bruno Rotoli, Guido Rossi, Pia Ragno.   

Abstract

We investigated the involvement of the urokinase-type plasminogen-activator receptor (uPAR) in granulocyte-colony-stimulating factor (G-CSF)-induced mobilization of CD34+ hematopoietic stem cells (HSCs) from 16 healthy donors. Analysis of peripheral blood mononuclear cells (PBMNCs) showed an increased uPAR expression after G-CSF treatment in CD33+ myeloid and CD14+ monocytic cells, whereas mobilized CD34+ HSCs remained uPAR negative. G-CSF treatment also induced an increase in serum levels of soluble uPAR (suPAR). Cleaved forms of suPAR (c-suPAR) were released in vitro by PBMNCs and were also detected in the serum of G-CSF-treated donors. c-suPAR was able to chemoattract CD34+ KG1 leukemia cells and CD34+ HSCs, as documented by their in vitro migratory response to a chemotactic suPAR-derived peptide (uPAR84-95). uPAR84-95 induced CD34+ KG1 and CD34+ HSC migration by activating the high-affinity fMet-Leu-Phe (fMLP) receptor (FPR). In addition, uPAR84-95 inhibited CD34+ KG1 and CD34+ HSC in vitro migration toward the stromal-derived factor 1 (SDF1), thus suggesting the heterologous desensitization of its receptor, CXCR4. Finally, uPAR84-95 treatment significantly increased the output of clonogenic progenitors from long-term cultures of CD34+ HSCs. Our findings demonstrate that G-CSF-induced upregulation of uPAR on circulating CD33+ and CD14+ cells is associated with increased uPAR shedding, which leads to the appearance of serum c-suPAR. c-suPAR could contribute to the mobilization of HSCs by promoting their FPR-mediated migration and by inducing CXCR4 desensitization.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15494432     DOI: 10.1182/blood-2004-06-2424

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  42 in total

1.  Inflammation and N-formyl peptide receptors mediate the angiogenic activity of human vitreous humour in proliferative diabetic retinopathy.

Authors:  Sara Rezzola; Michela Corsini; Paola Chiodelli; Anna Cancarini; Imtiaz M Nawaz; Daniela Coltrini; Stefania Mitola; Roberto Ronca; Mirella Belleri; Liliana Lista; Dario Rusciano; Mario De Rosa; Vincenzo Pavone; Francesco Semeraro; Marco Presta
Journal:  Diabetologia       Date:  2017-01-13       Impact factor: 10.122

2.  Soluble Urokinase Receptor Is Released Selectively by Glioblastoma Cells That Express Epidermal Growth Factor Receptor Variant III and Promotes Tumor Cell Migration and Invasion.

Authors:  Andrew S Gilder; Karra A Jones; Jingjing Hu; Lei Wang; Clark C Chen; Bob S Carter; Steven L Gonias
Journal:  J Biol Chem       Date:  2015-04-02       Impact factor: 5.157

Review 3.  Regulation of CXCR4 signaling.

Authors:  John M Busillo; Jeffrey L Benovic
Journal:  Biochim Biophys Acta       Date:  2006-11-10

4.  Rapid mobilization of hematopoietic progenitors by AMD3100 and catecholamines is mediated by CXCR4-dependent SDF-1 release from bone marrow stromal cells.

Authors:  Ayelet Dar; Amir Schajnovitz; Kfir Lapid; Alexander Kalinkovich; Tomer Itkin; Aya Ludin; Wei-Ming Kao; Michela Battista; Melania Tesio; Orit Kollet; Neta Netzer Cohen; Raanan Margalit; Eike C Buss; Francoise Baleux; Shinya Oishi; Nobutaka Fujii; Andre Larochelle; Cynthia E Dunbar; Hal E Broxmeyer; Paul S Frenette; Tsvee Lapidot
Journal:  Leukemia       Date:  2011-04-15       Impact factor: 11.528

5.  The cross-talk between the urokinase receptor and fMLP receptors regulates the activity of the CXCR4 chemokine receptor.

Authors:  Nunzia Montuori; Katia Bifulco; Maria Vincenza Carriero; Claudio La Penna; Valeria Visconte; Daniela Alfano; Ada Pesapane; Francesca Wanda Rossi; Salvatore Salzano; Guido Rossi; Pia Ragno
Journal:  Cell Mol Life Sci       Date:  2010-10-24       Impact factor: 9.261

6.  Circulating soluble urokinase plasminogen activator receptor levels and peripheral arterial disease outcomes.

Authors:  Ayman Samman Tahhan; Salim S Hayek; Pratik Sandesara; Jamal Hajjari; Muhammad Hammadah; Wesley T O'Neal; Heval M Kelli; Ayman Alkhoder; Nima Ghasemzadeh; Yi-An Ko; Hiroshi Aida; Mohamad Mazen Gafeer; Naser Abdelhadi; Kareem Hosny Mohammed; Keyur Patel; Shipra Arya; Jochen Reiser; Viola Vaccarino; Laurence Sperling; Arshed Quyyumi
Journal:  Atherosclerosis       Date:  2017-06-08       Impact factor: 5.162

7.  Increased soluble urokinase plasminogen activator receptor (suPAR) is associated with thrombosis and inhibition of plasmin generation in paroxysmal nocturnal hemoglobinuria (PNH) patients.

Authors:  Elaine M Sloand; Loretta Pfannes; Phillip Scheinberg; Kenneth More; Colin O Wu; McDonald Horne; Neal S Young
Journal:  Exp Hematol       Date:  2008-10-26       Impact factor: 3.084

Review 8.  International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family.

Authors:  Richard D Ye; François Boulay; Ji Ming Wang; Claes Dahlgren; Craig Gerard; Marc Parmentier; Charles N Serhan; Philip M Murphy
Journal:  Pharmacol Rev       Date:  2009-06-04       Impact factor: 25.468

9.  Membrane-anchored uPAR regulates the proliferation, marrow pool size, engraftment, and mobilization of mouse hematopoietic stem/progenitor cells.

Authors:  Marc Tjwa; Nicolai Sidenius; Rute Moura; Sandra Jansen; Koen Theunissen; Annapaola Andolfo; Maria De Mol; Mieke Dewerchin; Lieve Moons; Francesco Blasi; Catherine Verfaillie; Peter Carmeliet
Journal:  J Clin Invest       Date:  2009-03-09       Impact factor: 14.808

10.  Characterisation of urokinase plasminogen activator receptor variants in human airway and peripheral cells.

Authors:  Ceri E Stewart; Ian Sayers
Journal:  BMC Mol Biol       Date:  2009-07-28       Impact factor: 2.946

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.